Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-jun NH2-terminal kinase inhibitors

被引：68

作者：

Zhao, Hongyu ^{[1
]}

Serby, Michael D. ^{[1
]}

Xin, Zhili ^{[1
]}

Szczepankiewicz, Bruce G. ^{[1
]}

Liu, Mei ^{[1
]}

Kosogof, Christi ^{[1
]}

Liu, Bo ^{[1
]}

Nelson, Lissa T. J. ^{[1
]}

Johnson, Eric F. ^{[1
]}

Wang, Sanyi ^{[1
]}

Pederson, Terry ^{[1
]}

Gum, Rebecca J. ^{[1
]}

Clampit, Jill E. ^{[1
]}

Haasch, Deanna L. ^{[1
]}

Abad-Zapatero, Cele ^{[1
]}

Fry, Elizabeth H. ^{[1
]}

Rondinone, Cristina ^{[1
]}

Trevillyan, James M. ^{[1
]}

Sham, Hing L. ^{[1
]}

Liu, Gang ^{[1
]}

机构：

[1] Abbott Labs, Metab Dis Res, Global Pharmaceut Res & Dev, Abbott Pk, IL 60064 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2006年 / 49卷 / 15期

关键词：

D O I：

10.1021/jm060465l

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

C-Jun NH2 terminal kinases (JNKs) are important cell signaling enzymes. JNK1 plays a central role in linking obesity and insulin resistance. JNK2 and JNK3 may be involved in inflammatory and neurological disorders, respectively. Small-molecule JNK inhibitors could be valuable tools to study the therapeutic benefits of inhibiting these enzymes and as leads for potential drugs targeting JNKs. In this report, we disclose a series of potent and highly selective JNK inhibitors with good pharmacokinetic profiles.

引用

页码：4455 / 4458

页数：4

共 32 条

[1] Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action
Aguirre, V
Werner, ED
Giraud, J
Lee, YH
Shoelson, SE
White, MF
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (02) : 1531 - 1537
[2] The c-Jun NH2-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser307
Aguirre, V
Uchida, T
Yenush, L
Davis, R
White, MF
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (12) : 9047 - 9054
[3] FUNCTIONAL-GROUP CONTRIBUTIONS TO DRUG RECEPTOR INTERACTIONS
ANDREWS, PR
CRAIK, DJ
MARTIN, JL
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 1984, 27 (12) : 1648 - 1657
[4] The c-Jun N-terminal protein kinase family of mitogen-activated protein kinases (JNK MAPKs)
Barr, RK
Bogoyevitch, MA
[J]. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2001, 33 (11) : 1047 - 1063
[5] JNK: a new therapeutic target for diabetes
Bennett, BL
Satoh, Y
Lewis, AJ
[J]. CURRENT OPINION IN PHARMACOLOGY, 2003, 3 (04) : 420 - 425
[6] Defective T cell differentiation in the absence of Jnk1
Dong, C
Yang, DD
Wysk, M
Whitmarsh, AJ
Davis, RJ
Flavell, RA
[J]. SCIENCE, 1998, 282 (5396) : 2092 - 2095
[7] THE CONDENSATION OF SODIUM NITROMALONALDEHYDE WITH CYANOACETAMIDE
FANTA, PE
STEIN, RA
[J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1955, 77 (04) : 1045 - 1046
[8] Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase
Gaillard, P
Jeanclaude-Etter, I
Ardissone, V
Arkinstall, S
Cambet, Y
Camps, M
Chabert, C
Church, D
Cirillo, R
Gretener, D
Halazy, S
Nichols, A
Szyndralewiez, C
Vitte, PA
Gotteland, JP
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (14) : 4596 - 4607
[9] Selective interaction of JNK protein kinase isoforms with transcription factors
Gupta, S
Barrett, T
Whitmarsh, AJ
Cavanagh, J
Sluss, HK
Derijard, B
Davis, RJ
[J]. EMBO JOURNAL, 1996, 15 (11) : 2760 - 2770
[10] A central role for JNK in obesity and insulin resistance
Hirosumi, J
Tuncman, G
Chang, LF
Görgün, CZ
Uysal, KT
Maeda, K
Karin, M
Hotamisligil, GS
[J]. NATURE, 2002, 420 (6913) : 333 - 336

← 1 2 3 4 →